In:
Oncology, S. Karger AG, Vol. 71, No. 3-4 ( 2006), p. 229-236
Abstract:
〈 i 〉 Objectives: 〈 /i 〉 A dose-finding study of a new cisplatin/vinorelbine schedule was done to increase activity of the combination, and improve compliance of non-small-cell lung cancer patients. 〈 i 〉 Methods: 〈 /i 〉 Beginning with cisplatin 40 mg/m 〈 sup 〉 2 〈 /sup 〉 on days 1, 2 and vinorelbine 20 mg/m 〈 sup 〉 2 〈 /sup 〉 on days 1, 3, increasing dose levels up to the maximum tolerated dose (MTD) were tested in a series of 6-patient cohorts. If 3 of 6 patients experienced dose-limiting toxicity in the first 3 cycles, the previous dose was considered the recommended dose (RD). Once the MTD was reached, granulocyte-colony-stimulating factor was prophylactically added to the treatment of a new patient cohort to improve the therapeutic ratio. 〈 i 〉 Results: 〈 /i 〉 We enrolled 35 stage IIIA/B or IV patients between August 2001 and February 2002. The RD was cisplatin 45 mg/m 〈 sup 〉 2 〈 /sup 〉 and vinorelbine 25 mg/m 〈 sup 〉 2 〈 /sup 〉 , with relative dose intensities (RDIs) of 95 and 97%, respectively, and an actual received dose intensity (ARDI) of 28.62 and 16.07 mg/m 〈 sup 〉 2 〈 /sup 〉 /week, respectively. Overall grade 3–4 toxicities were: neutropenia (71%), febrile neutropenia (25%), anemia (8%), and constipation (17%). The overall response rate was 64.3% (CI: 44.1–81.4%). 〈 i 〉 Conclusions: 〈 /i 〉 ARDI and RDI of our modified cisplatin/vinorelbine regimen were not inferior to those of conventional weekly schedules; its acceptable toxicity profile and manageability may justify its use in clinical practice.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2006
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Permalink
